Update History2026/10/09 Article publishedIntroductionHello everyone!Do you ever find yourself wondering what the name of a ...
GLP-1 and GIP agonist, VK2735, has the potential to carve out a niche in the highly competitive weight-loss market by delivering rapid weight loss and serving as a maintenance therapy, either ...
People receiving weekly doses of Viking's investigational obesity drug, VK2735, lost 16% to 19% of their bodyweight after 21 weeks, compared with roughly 0% for placebo. Moreover, participants' weight ...
Leave it to a viking to take on two jötnar, as giants were called in Old Norse. The GLP-1 drug market radically transformed the way healthcare providers treat obesity, unlocking billions in revenue ...
VK2735 patients kept up to 97% of lost weight with shots every other week and up to 90% with monthly shots. Aronne called stopping treatment the “biggest threat” to keeping weight off and said fewer ...
Keep up with the top pharma business news of the week. On the go. Scrip brings you a weekly bulletin of top picks.
Viking stock catapulted Tuesday on "stellar" test results for its weight-loss shot, sending shares of rival Novo (NVO) lower. The study examined a every-other-week and monthly doses of Viking ...
One of the persistent frustrations with GLP-1 weight loss drugs is the commitment they require. Weekly injections, strict maintenance dosing, and the knowledge that if you stop, the weight often comes ...
An experimental drug developed by Viking Therapeutics helped people maintain their weight loss even after stretching the doses to once a month or every other week. Viking’s stock VKTX closed 35.7% ...
Shares of Viking Therapeutics surged in premarket and early trade after the company released topline results on its experimental obesity drug VK2735. Patients who moved from weekly injections to every ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results